Although BCL-XL represents a well-validated therapeutic target, the clinical use of BCL-XL inhibitors (such as ABT263) was limited due to thrombocytopenia caused by inhibition of BCL-XL in platelets (see above). The gene discussed is BCL2L1; the disease is Thrombocytopenia.